ZA200602497B - Pharmaceutical compositions of moxifloxacin and processes for their preparation - Google Patents
Pharmaceutical compositions of moxifloxacin and processes for their preparation Download PDFInfo
- Publication number
- ZA200602497B ZA200602497B ZA200602497A ZA200602497A ZA200602497B ZA 200602497 B ZA200602497 B ZA 200602497B ZA 200602497 A ZA200602497 A ZA 200602497A ZA 200602497 A ZA200602497 A ZA 200602497A ZA 200602497 B ZA200602497 B ZA 200602497B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical composition
- water insoluble
- substantially water
- moxifloxacin
- tablet
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 24
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical group COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 title claims description 23
- 229960003702 moxifloxacin Drugs 0.000 title claims description 19
- 238000002360 preparation method Methods 0.000 title description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 19
- 239000000314 lubricant Substances 0.000 claims description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 19
- 239000007884 disintegrant Substances 0.000 claims description 16
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 15
- 229920000881 Modified starch Polymers 0.000 claims description 15
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 15
- 239000011230 binding agent Substances 0.000 claims description 15
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 15
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 235000010980 cellulose Nutrition 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 239000003086 colorant Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- -1 disintegerants Substances 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000019426 modified starch Nutrition 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- 150000005846 sugar alcohols Chemical class 0.000 claims description 5
- 150000008163 sugars Chemical class 0.000 claims description 5
- 239000000454 talc Substances 0.000 claims description 5
- 229910052623 talc Inorganic materials 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 3
- SKZIMSDWAIZNDD-WJMOHVQJSA-N 7-[(4as,7as)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrate;hydrochloride Chemical compound O.Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 SKZIMSDWAIZNDD-WJMOHVQJSA-N 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 6
- 239000008213 purified water Substances 0.000 description 12
- 229920002554 vinyl polymer Polymers 0.000 description 11
- 238000009472 formulation Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 description 5
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 description 5
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 4
- 229940062316 avelox Drugs 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 4
- 229940038472 dicalcium phosphate Drugs 0.000 description 4
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000007916 tablet composition Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010061736 Bronchitis bacterial Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002706 dry binder Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004310 lactic acid Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940006361 moxifloxacin 400 mg Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000001117 sulphuric acid Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1099DE2003 | 2003-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200602497B true ZA200602497B (en) | 2007-09-26 |
Family
ID=34259939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200602497A ZA200602497B (en) | 2003-09-03 | 2006-03-27 | Pharmaceutical compositions of moxifloxacin and processes for their preparation |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1663226A1 (fr) |
WO (1) | WO2005020998A1 (fr) |
ZA (1) | ZA200602497B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006015545A1 (fr) * | 2004-08-11 | 2006-02-16 | Shenzhen Tys R & D Co., Ltd. | Capsule de gelatine de moxifloxacin et procede pour sa preparation |
WO2007033515A1 (fr) * | 2005-09-21 | 2007-03-29 | Shenzhen Tys R & D Co., Ltd. | Formulation orale contenant de la moxifloxacine et son procédé de préparation |
WO2007033522A1 (fr) * | 2005-09-21 | 2007-03-29 | Shenzhen Tys R & D Co., Ltd. | Formulation de gélule contenant de la moxifloxacine et son procédé de préparation |
CN100363001C (zh) * | 2005-09-21 | 2008-01-23 | 深圳市天一时科技开发有限公司 | 一种莫西沙星胶囊剂及其制备方法 |
WO2009135646A2 (fr) * | 2008-05-05 | 2009-11-12 | Farmaprojects, Sa | Compositions pharmaceutiques stables et procédés de préparation desdites compositions adaptés à l’échelle industrielle |
WO2010066385A1 (fr) | 2008-12-08 | 2010-06-17 | Ratiopharm Gmbh | Moxifloxacine compactée |
CN102247313A (zh) * | 2010-06-11 | 2011-11-23 | 北京润德康医药技术有限公司 | 一种以莫西沙星为活性成分的口服缓释固体制剂 |
BRPI1106900A2 (pt) | 2011-12-26 | 2013-11-05 | Ems Sa | Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção |
GR1008169B (el) * | 2013-03-19 | 2014-04-08 | "Φαρματεν Α.Β.Ε.Ε.", | Φαρμακευτικο σκευασμα περιεχον εναν αντιβακτηριακο παραγοντα φθοριοκινολονης και μεθοδος για την παρασκευη αυτου |
CN104622821B (zh) * | 2013-11-13 | 2018-04-10 | 武汉先路医药科技有限公司 | 解决溶出行为受制粒时间影响问题的莫西沙星片剂配方 |
CN106074413A (zh) * | 2016-07-20 | 2016-11-09 | 南通雅本化学有限公司 | 一种含有莫西沙星的药物组合物 |
CN109045034B (zh) * | 2018-09-29 | 2021-04-13 | 哈尔滨珍宝制药有限公司 | 一种盐酸莫西沙星药物组合物及其制备方法和应用 |
EP4164626A4 (fr) * | 2020-06-15 | 2024-07-03 | Mylan Laboratories Ltd | Composition antibactérienne polythérapeutique et méthode de thérapie antibactérienne |
EP4164645A4 (fr) * | 2020-06-15 | 2024-07-10 | The Global Alliance For Tb Drug Dev Inc | Composition antibactérienne combinée et procédé de thérapie antibactérienne |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3906365A1 (de) * | 1988-07-15 | 1990-01-18 | Bayer Ag | 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe |
IL142642A0 (en) * | 1998-11-10 | 2002-03-10 | Bayer Ag | Pharmaceutical moxifloxacin preparation |
-
2004
- 2004-09-03 WO PCT/IB2004/002875 patent/WO2005020998A1/fr not_active Application Discontinuation
- 2004-09-03 EP EP04769278A patent/EP1663226A1/fr not_active Withdrawn
-
2006
- 2006-03-27 ZA ZA200602497A patent/ZA200602497B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1663226A1 (fr) | 2006-06-07 |
WO2005020998A1 (fr) | 2005-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200602497B (en) | Pharmaceutical compositions of moxifloxacin and processes for their preparation | |
KR101424843B1 (ko) | 의약 조성물 | |
US5814339A (en) | Film coated tablet of paracetamol and domperidone | |
EP1335707A2 (fr) | Nouvelles formulations de carvedilol | |
EP2468361A1 (fr) | Formulations de vildagliptine | |
GB2414668A (en) | Sustained release delivery system for tetracycline compounds | |
CZ301812B6 (cs) | Orálne aplikovatelný prípravek, obsahující chinolonová antibiotika a zpusob jeho výroby | |
US20040019096A1 (en) | Novel formulations of carvedilol | |
US7943585B2 (en) | Extended release antibiotic composition | |
CZ124497A3 (en) | Oral preparations with prolonged release of cisaprid | |
WO2009027786A2 (fr) | Formes posologiques matricielles de varénicline | |
CA3224531A1 (fr) | Composition pharmaceutique comprenant une association de sitagliptine et d'empagliflozine | |
KR101811700B1 (ko) | 레보드로프로피진 함유 서방정 및 이의 제조방법 | |
WO2013157841A1 (fr) | Comprimé à libération prolongée contenant de la lévodropropizine et procédé pour préparer celui-ci | |
US20050053657A1 (en) | Controlled release formulation of clarithromycin or tinidazol | |
AU2005235237A1 (en) | Clarithromycin extended release formulation | |
WO2022153330A1 (fr) | Compositions pharmaceutiques comprenant de l'acalabrutinib | |
US20110223245A1 (en) | Controlled-release formulations of pramipexole | |
US20120178810A1 (en) | Extended release formulation of an antiepileptic agent | |
CA2642414C (fr) | Composition pharmaceutique contenant de l'irbesartan a liberation rapide | |
WO2011086577A2 (fr) | Composition pharmaceutique de moxifloxacine et ses sels pharmaceutiquement acceptables | |
EP1560568B1 (fr) | Compositions pharmaceutiques a liberation controlee contenant de l'alginate de sodium et de l'alginate de sodium et calcium | |
JPWO2013147135A1 (ja) | 放出制御医薬組成物 | |
US20080206329A1 (en) | Modified Release Ciprofloxacin Compositions | |
WO2010108845A1 (fr) | Composition pharmaceutique contenant de la levodopa, de l'entacapone et de la carbidopa |